Evaluation of Tau imaging in staging Alzheimer disease and revealing interactions between β-Amyloid and tauopathy

JAMA Neurology

Volumn 73, Issue 9, 2016, Pages 1070-1077

  Wang, Liang ^a   Benzinger, Tammie L ^a,b   Su, Yi ^b   Christensen, Jon ^b   Friedrichsen, Karl ^b   Aldea, Patricia ^a,b   McConathy, Jonathan ^a,c   Cairns, Nigel J ^a   Fagan, Anne M ^a   Morris, John C ^a   Ances, Beau M ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c University of Alabama   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; FLORTAUCIPIR F 18; TAU PROTEIN; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; AMYLOID BETA-PROTEIN (1-42); CARBOLINE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; BRAIN REGION; BRAIN SIZE; CLINICAL DEMENTIA RATING; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); FEMALE; HIPPOCAMPUS; HUMAN; INFERIOR PARIETAL LOBULE; INFERIOR TEMPORAL CORTEX; LATERAL TEMPORAL LOBE; MAJOR CLINICAL STUDY; MALE; MEDIAL TEMPORAL LOBE; NEUROIMAGING; POSITRON EMISSION TOMOGRAPHY; POSTERIOR MEDIAL LOBULE; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE RATIO; SUPERIOR PARIETAL LOBULE; TAUOPATHY; CEREBROSPINAL FLUID; DIAGNOSTIC IMAGING; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CARBOLINES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; SEVERITY OF ILLNESS INDEX; TAU PROTEINS; TAUOPATHIES;

EID: 84998694318     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2016.2078     Document Type: Article

References (42)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82(4):239-259.
2. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-Associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389-404.
3. Thal DR, OrantesM, Braak H. Phases of Aβ-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58 (12):1791-1800.
4. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimers disease. Ann Neurol. 1999;45(3):358-368.
5. Delacourte A, David JP, Sergeant N, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimers disease. Neurology. 1999;52(6):1158-1165.
6. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann Neurol. 2006;59(3):512-519.
7. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimers disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3): 306-319.
8. Buerger K, Ewers M, PirttilT, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimers disease. Brain. 2006;129(pt 11):3035-3041.
9. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimers disease: recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement. 2011;7(3): 280-292.
10. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-Tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34 (2):457-468.
11. Xia CF, Arteaga J, Chen G, et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimers disease. Alzheimers Dement. 2013;9(6):666-676.
12. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79(6):1094-1108.
13. Okamura N, Furumoto S, Fodero-TavolettiMT, et al. Non-invasive assessment of Alzheimers disease neurofibrillary pathology using 18F-THK5105 PET. Brain. 2014;137(pt 6):1762-1771.
14. MarquiM, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol. 2015;78(5): 787-800.
15. Villemagne VL, Fodero-TavolettiMT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol. 2015;14(1):114-124.
16. Ossenkoppele R, Schonhaut DR, Baker SL, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol. 2015;77(2): 338-342.
17. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimers disease. Ann Neurol. 2016;79 (1):110-119.
18. Schl M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971-982.
19. Schwarz AJ, Yu P, Miller BB, et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139(pt 5):1539-1550.
20. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimers disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19(3):497-510.
21. Vemuri P, Whitwell JL, Kantarci K, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. Neuroimage. 2008;42(2):559-567.
22. Wang L, Benzinger TL, Hassenstab J, et al. Spatially distinct atrophy is linked to β-Amyloid and tau in preclinical Alzheimer disease. Neurology. 2015;84(12):1254-1260.
23. JagustW. Time for tau. Brain. 2014;137(pt 6): 1570-1571.
24. Jack CR Jr, Knopman DS, JagustWJ, et al. Tracking pathophysiological processes in Alzheimers disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12(2):207-216.
25. Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: Time, space and "wingmen." Nat Neurosci. 2015;18(6):800-806.
26. Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimers disease: implications for prevention trials. Neuron. 2014;84 (3):608-622.
27. Delacourte A, Sergeant N, Wattez A, et al. Tau aggregation in the hippocampal formation: An ageing or a pathological process? Exp Gerontol. 2002;37(10-11):1291-1296.
28. Lace G, Savva GM, Forster G, et al; MRC-CFAS. Hippocampal tau pathology is related to neuroanatomical connections: An ageing population-based study. Brain. 2009;132(pt 5): 1324-1334.
29. Jack CR Jr, Wiste HJ, Weigand SD, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81(20):1732-1740.
30. Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): A common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755-766.
31. Berg L, McKeel DWJr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimers disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998;55 (3):326-335.
32. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.
33. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006; 20(4):210-216.
34. Su Y, Blazey TM, Snyder AZ, et al. Quantitative amyloid imaging using image-derived arterial input function. PLoS One. 2015;10(4):e0122920.
35. Su Y, Blazey TM, Snyder AZ, et al; Dominantly Inherited Alzheimer Network. Partial volume correction in quantitative amyloid imaging. Neuroimage. 2015;107:55-64.
36. Team RDC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
37. Jack CR Jr, Vemuri P, Wiste HJ, et al; Alzheimers Disease Neuroimaging Initiative. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol. 2011;68(12):1526-1535.
38. Chelat G, Villemagne VL, Villain N, et al; AIBL Research Group. Accelerated cortical atrophy in cognitively normal elderly with high β-Amyloid deposition. Neurology. 2012;78(7):477-484.
39. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18(4):351-357.
40. Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol. 2012;71(5): 362-381.
41. Jack CR Jr, Barkhof F, Bernstein MA, et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimers disease. Alzheimers Dement. 2011;7(4):474-485.
42. de Calignon A, Polydoro M, Suez-Calvet M, et al. Propagation of tau pathology in a model of early Alzheimers disease. Neuron. 2012;73(4): 685-697.